Geologists Found the Fossil of a Stunning 30-Foot Sea Dragon in Mississippi, of All Places
Geologists recently discovered the fossil of a Cretaceous-era mosasaur vertebra near Starkville, Mississippi.
The experts believe the apex predator of the ancient seas could have weighed 20,000 pounds and been 50 feet long.
The Late Cretaceous-era Mosasaurus hoffmannii was known to eat others of its own species.
Whatever you want to call the Mosasaurus hoffmannii—a giant mosasaur, a massive water dragon, maybe even a sea monster—just know that it was one big dino, and we've got the bones to prove it. Geologists in Mississippi recently discovered the vertebra of the Late Cretaceous-era water dinosaur, which could reach up to 50 feet long and weigh 20,000 pounds at its largest. It was truly an apex predator extraordinaire.
The find came in the fossil-rich outcrops of northeast Mississippi, near Starkville in the Prairie Bluff Formation, according to a statement from the Mississippi Department of Environmental Quality, and the discovery sheds new light on the 'giant sea lizard' that was a contemporary of the Tyrannosaurus rex, Velociraptor, and Triceratops.
This Cretaceous carnivore was not to be messed with. It had jaws lined with 60 dagger-like pointed teeth curved inward—with additional rows of teeth at the roof of the back of their mouths to help secure large prey, including other mosasaurs—and the subaquatic dinos could regrow the teeth, which they frequently lost while hunting.
'Mosasaurs were sea dragons, both large and small, and were truly the apex predators dominating the various environments of the seas of this time,' according to the state's geologists. 'While the dinosaurs ruled the land, these Mesozoic-era oceans were likely the most dangerous of any time in the entire history of our planet.'
The recent discovery was 'from a true giant,' the team said, adding it belonged to a M. hoffmannii, one of the largest and last mosasaurs during the Cretaceous period. Its size, coupled with its agility and speed in the water, made it 'one of the most formidable marine predators to ever swim in our planet's oceans.'
Noting that in a period where much of Mississippi was believed covered by warm, tropical ocean waters, mosasaurs were akin to a giant lizard that was specialized in this environment.
This specimen belongs to the largest-ever M. hoffmannii recorded in the state and would have been larger than most dinosaurs on land. 'This is a true, true sea monster,' James Starnes of the Mississippi Department of Environmental Quality's Office of Geology, told the Hattiesburg American. 'This is about as big as mosasaurs get.'
George Phillips, paleontology curator at the Mississippi Museum of Natural Science, told the Hattiesburg American, this find—with a backbone seven inches at its widest point—was likely at least 30 feet long, though the M. hoffmannii is believed to be able to reach 50 feet in length.
'We find them from time to time, but to find one this size is phenomenal,' Starnes said. 'The transparent size of this thing blew us away.'
The team located the vertebra in mud while building a three-dimensional map of the site's geological layers. It may have sat there for about 66 million years, the team believes, ever since the species went extinct at the end of the Cretaceous period.
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
American Military News
13 hours ago
- American Military News
Video: World War I submarine found off San Diego coast
The USS F-1, a World War I-era U.S. Navy submarine, was recently discovered by researchers off the cost of San Diego, California. The discovery comes 108 years after the submarine was 'lost at sea' in a training accident in December of 1917. In a recent press release, Woods Hole Oceanographic Institution (WHOI) announced, 'A deep-sea training and engineering dive off the coast of San Diego provided an opportunity for never-before-seen imagery of the U.S. Navy submarine USS F-1, lost at sea in an accident on December 17, 1917, that resulted in the death of 19 crew members.' According to the press release, WHOI researchers captured images of the World War I-era Navy submarine by using 'Sentry,' an autonomous underwater vehicle, and 'Alvin,' a human-occupied vehicle, to access the remains of the submarine located under more than 1,300 feet of water. 'Advanced ocean technology and simple teamwork played a big part in delivering these new images,' Bruce Strickrott, manager of the Alvin Group at WHOI and the senior pilot who helped lead the recent expedition, said. 'Once we identified the wreck and determined it was safe to dive, we were able to capture never-before-seen perspectives of the sub. As a U.S. Navy veteran, it was a profound honor to visit the wreck of the F-1 with our ONR and NHHC colleagues aboard Alvin.' READ MORE: Pics: Surprising WWII shipwreck finds revealed WHOI explained that the recent expedition was part of a training and engineering mission intended to give pilots of the underwater submersibles an opportunity to increase their piloting skills and develop technology for underwater research. 'It was an incredibly exciting and humbling experience to visit these historically significant wrecks and to honor the sacrifice of these brave American Sailors,' Naval History and Heritage Command (NHHC) Underwater Archaeologist Brad Krueger said. 'All of us at the NHHC are grateful for this collaboration, which also enabled us to document and assess the condition of the crafts.' According to the press release, the crew on the Atlantis, which was stationed above the location of the remains of the USS F-1, held a remembrance ceremony in honor of the 19 Navy members who were killed in the training incident in 1917. 'History and archaeology are all about people and we felt it was important to read their names aloud,' Krueger stated. 'The Navy has a solemn responsibility to ensure the legacies of its lost Sailors are remembered.' A video shared on X, formerly Twitter, by WHOI shows the new footage of the USS F-1 submarine as well as part of the ceremony held in honor of the 19 Navy members.
Medscape
14 hours ago
- Medscape
Is Albuminuria Screening the Answer to Tackling Unseen CKD?
VIENNA — Only 7%-20% of people with chronic kidney disease (CKD) in the US are aware of their condition; meanwhile, the disease is projected to become the fifth leading cause of death globally by 2050. But what is the best way to change these statistics? Facing off on opposite sides of a debate at 62nd European Renal Association (ERA) Congress 2025 on whether or not population screening of albuminuria is the answer were Ronald T. Gansevoort, MD, PhD, University Medical Center Groningen, Groningen, the Netherlands, and Joseph A. Vassalotti, MD, Icahn School of Medicine at Mount Sinai, New York City. While the two speakers agreed on the importance of early detection of CKD and the limitations of current practice, they diverged on the best path forward. The Case for Population Screening 'Albuminuria is by far the strongest predictor for kidney function decline,' said Gansevoort, who argued for broad screening. 'It can occur in an early stage of kidney disease, when kidney function is still normal,' he said, adding that it is often accompanied by as yet unknown — or poorly controlled — diabetes, hypertension, hyperlipidemia, and even cardiovascular disease. He illustrated the gravity of the situation with a stark comparison: Patients on dialysis have 5-year survival rates similar to those of patients with colorectal cancer. Worse, survival is improving slightly in patients with cancer, whereas survival in patients on dialysis has not improved at all over the past few decades, he noted. Gansevoort stressed the importance of identifying individuals at risk before a decline in the glomerular filtration rate begins, pointing to the increased availability of effective interventions, including SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists. To demonstrate the feasibility of screening, he presented results from THOMAS, a Dutch prospective, randomized, open-label implementation study comparing two home-based screening methods. Using a urine collection kit returned by post, the study achieved a 59% participation rate and identified confirmed high albuminuria in 3.3% of participants. Among those with albuminuria, 90% had newly diagnosed or poorly controlled comorbidities such as hypertension or high cholesterol. Yet only 54% of referred patients actually visited their general practitioner. There's definitely room for improvement there, Gansevoort acknowledged. Nonetheless, he argued that population screening was cost-effective when done at home. The researchers from THOMAS calculated a cost of €9225 per quality-adjusted life-year (QALY), far below typical European thresholds. 'It's already cost-effective,' he noted, adding that integrating albuminuria testing into existing national screening programs, such as those for colorectal cancer or cardiovascular disease, could further boost cost-effectiveness and increase participation. He described the newly launched Check@Home study — a collaborative effort by the Dutch CardioVascular Alliance, the Dutch Heart Foundation, the Kidney Foundation, and the Diabetes Research Foundation — that combines screening for both CKD and cardiovascular disease. He also highlighted the recently begun CASCADE CKD study, which uses a single at-home kit incorporating both urine and fecal collection to screen simultaneously for CKD and colorectal cancer. 'How easy would it be in the same package to have a second tube to collect some urine and to detect patients with chronic kidney disease?' he asked. By sharing logistical infrastructure, 'It will definitely improve cost-effectiveness even further,' he noted. The Case Against Vassalotti, speaking against general population screening, began with a concession: 'I'm not against population screening for albuminuria,' he said. 'Rather, I think case finding among risk groups is more feasible, sustainable, and impactful.' He emphasized the importance of context, asking the audience to consider 'the public, the patients, the primary care clinicians, and the policymakers. In the US, even among those diagnosed, only half receive urine albumin testing.' 'We're not even doing a good job managing people with CKD,' he said. 'We should implement better case finding or opportunistic screening to start with.' Cost was another sticking point. Vassalotti cited a US study that used Markov models to assess population-wide CKD screening and put the cost at $86,300 per QALY for adults aged 55 years or older, a figure above commonly accepted thresholds. 'Implementation was assumed to be 100%,' he said, 'which in the US is quite a stretch.' Vassalotti praised Gansevoort's THOMAS study but questioned its scalability. 'How can you screen the general population if only 59% participate?' he asked. He added that participation in the US might be even lower, given the lack of public awareness and fragmented health infrastructure. He concluded by advocating for primary care engagement and better CKD education. 'Perceived risk will help us manage the risk condition,' he said. 'And that will result in more awareness, increased detection, and improved management.' Agreement on Need for Action In a rebuttal, Gansevoort reiterated that his model was already more cost-effective than those cited by Vassalotti. 'We do it in the home setting, making it far less costly,' he said. He also called for a more pragmatic view on participation. 'We are not going to save everybody,' he said. 'But should we not save many people because some do not like to be screened?' Vassalotti, in turn, emphasized the need to work on education, for the public, patients, and clinicians alike, before expanding screening. 'How can you screen the public for kidney disease,' he asked, 'when they don't even know what it is?' One key issue emerging from the closing discussion was how often screening should occur. 'It has not been decided yet,' Gansevoort admitted. 'We're looking into Markov models, perhaps a fixed interval or a patient-specific interval.' Vassalotti argued for simplicity: 'Annual screening is something that we can disseminate easily,' he said. 'Less frequent screening is more difficult to socialize.' Despite their differences, both speakers emphasized the need for action. 'We now have effective, sufficiently safe, and affordable treatments,' Gansevoort said. 'The present opportunistic screening approach has proven not to work.' For Vassalotti, the path forward must be grounded in context. 'Every country should develop its own approach,' he said. 'Whether it be population screening or case finding.' No funding was declared. Gansevoort declared having relationships with AbbVie, AstraZeneca, Baxter, Bayer, Dutch Kidney Foundation, Galapagos, Happitech, Health~Holland, Ipsen, Mironid, Roche, Sanofi Genzyme, Sandoz, and Otsuka Pharmaceuticals. Vassalotti declared having relationships with Novo Nordisk and Sanofi.
Yahoo
18 hours ago
- Yahoo
Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pharmacist delivering a specific medication to a patient in a specialty pharmacy. A pooled research found that sweat chloride (SwCl) levels below 60 mmol/L were associated with improved lung function, fewer exacerbations, and better nutritional and quality of life outcomes. Even larger numerical improvements were observed for SwCl below 30 mmol/L. According to post hoc data from Phase 3 trials, ALYFTREK outperformed TRIKAFTA® in terms of health outcomes for adults, adolescents, and children aged 6 to 11. Approximately 109,000 people worldwide, 94,000 of whom live in North America, Europe, and Australia, have cystic fibrosis. The majority of patients have at least one F508del mutation, which is the result of mutations in the CFTR gene. TRIKAFTA® is being donated in 14 lower-income countries, and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) medications currently serve over 75,000 people in 60+ countries, or almost two-thirds of eligible patients. It is among the stocks with the biggest upside. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
